TET Systems Holding GmbH & Co. KG (“TET Systems”), a worldwide leader in controlled gene expression, today announced that TET Systems and Novo Nordisk A/S have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk A/S, the use of the Tet Technology for its internal research activities.
TET Systems was founded by Prof. Dr. H. Bujard and his colleagues. Today, TET Systems’ technology is the most widely used method to control gene expression in higher organisms. 85% of the world's leading pharmaceutical companies license the Tet Technology for their internal R&D activities. The broad usage of the Tet Technology is demonstrated by more than 6,200 publications in peer-reviewed journals (June 2009).“We are very glad that we can add the Hagedorn Research Institute as part of Novo Nordisk, one of the premier global pharmaceutical companies with European headquarters, to our growing list of licensees”, stated Dr. E. Böhnlein, CEO of TET Systems. “This license agreement again shows that the Tet Technology provides a clear technological advantage to innovative biomedical research which translates into a strategic advantage for these pharmaceutical and biotech companies.”
TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems Holding owns a broad patent portfolio covering the technology organized in six patent families comprising 31 granted patents and 14 patent applications. TET Systems markets licenses to the Tet Technology through its subsidiary IP Merchandisers. To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.